Avacta celebrates success in US

Avacta announced that its newly appointed sales and marketing partner for Optim in North America, Pall Corporation, has secured its first Optim sale, to one of the 10 largest pharmaceutical companies in the US.

Optim allows drug developers to gain vital information about compounds using tiny samples, more cheaply and quickly than other methods.

Pall Life Sciences was appointed as distributor for North America in February.

Pall has been working with Avacta to generate new sales leads for Optim and has also been developing the US sales pipeline that Avacta had grown before the distribution agreement was signed.

In a statement, Avacta said: “In the short period since Pall’s appointment, the Optim sales pipeline in the US has doubled following successful marketing events. Avacta has completed the first phase of training for Pall’s sales and support teams and Pall has now closed its first sale to one of the largest global pharmaceutical companies.”

Alastair Smith, the chief executive of Avacta Group, said: “The US is the major market for Optim and I am delighted with the energetic and proactive start that Pall has made as our commercial partner in North America.

“The urgency with which the Pall team has undertaken sales and support training, the successful delivery of marketing events that have had a positive impact on the number of sales leads and the closing of the first sale following a trial of the instrument by the customer, is very encouraging.

“Today’s order means we have already met the target of 12 Optim sales in the current year. I look forward to reporting on further sales in due course and on the wider development of the commercial relationship with Pall.”